PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

I knew you would like that one bill. Glad you were able to get a chance to look at it....

Medelis: So the complete phase Ib sounds like a win-win-win since there is benefit to patients, investigators, and sponsors?

Dr. Von Hoff: Approaching the phase Ib as not just a toxicity trial but also a therapeutic opportunity is actually a quadruple win. CMOs benefit on the business side; they get better data faster, helping to drive fundraising and corporate development. Investigators have an opportunity to make an impact, delivering better care and the chance for a better outcome. And sponsors get answers faster and with less bureaucratic hassle since trial management is streamlined.

Last but not least, the complete phase Ib is an important opportunity to truly help patients. And in the end, that’s the most valuable win of all.

http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/